Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | University of California | 13 |
| 2 | Sumitomo Chemical Co Ltd | 6 |
| 3 | AstraZeneca PLC | 1 |
| 4 | Capital Medical University | 1 |
| 5 | Johnson and Johnson | 1 |
| 6 | University of Illinois System | 1 |
| 7 | Vanderbilt University | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 38 |
| 2 | A61K | Medicinal preparations | 29 |
| 3 | C07C | Acyclic and carbocyclic compounds | 20 |
| 4 | C07D | Heterocyclic compounds | 19 |
| 5 | G01N | Investigating / analysing materials | 9 |
| 6 | C40B | 6 | |
| 7 | C12N | Microorganisms, enzymes | 4 |
| 8 | Y02A | Climate change adaptation | 1 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS | 2004 | University of California | 57 |
| Modulation of anxiety through blockade of anandamide hydrolysis | 2007 | University of California | 21 |
| COMPOUNDS AND METHODS FOR TREATING NON-INFLAMMATORY PAIN USING PPARALPHA AGONISTS | 2005 | University of California | 23 |
| CANNABINERGIC LIPID LIGANDS | 2006 | 16 | |
| COMPOSITIONS AND METHODS OF TREATMENT USING MODULATORS OF MOTONUERON DISEASES | 2007 | 13 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 2 |
| 2017 | 6 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Daniele Piomelli | University of California, Irvine | 20 |
| 2 | Alexandros Makriyannis | University of Connecticut | 15 |
| 3 | Vincenzo Di Marzo | Istituto di Chimica Biomolecolare | 13 |
| 4 | Antonio Calignano | University of Naples Federico II | 8 |
| 5 | Fernando Rodrı́guez de Fonseca | Universidad Complutense de Madrid | 7 |
| 6 | Cecilia J. Hillard | Medical College of Wisconsin | 7 |
| 7 | Massimiliano Beltramo | Neurosciences Institute | 7 |
| 8 | Javier Fernández‐Ruíz | Universidad Complutense de Madrid | 6 |
| 9 | Leonardo B.M. Resstel | Universidade de São Paulo | 6 |
| 10 | Francisco Silveira Guimarães | Universidade de São Paulo | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Modulation of anxiety through blockade of anandamide hydrolysis | 2002 | 1294 | Neurotransmitter Receptor Influence on Behavior |
| Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin‐like activity | 2000 | 352 | Neuroscience and Neuropharmacology Research |
| Anandamide Induces Apoptosis in Human Cells via Vanilloid Receptors | 2000 | 350 | Neuroscience and Neuropharmacology Research |
| Endogenous cannabinoid signaling is essential for stress adaptation | 2010 | 349 | Cannabis and Cannabinoid Research |
| Structural determinants for recognition and translocation by the anandamide transporter | 1999 | 270 | Neuroscience and Neuropharmacology Research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of N-(4-hydroxyphenyl)icosa-5,8,11,14-tetraenamide?
Which organizations hold the most patents covering this compound?
What are the primary research applications indicated by patent classification?
Which researchers are most prominent in the literature on this compound?
What are the most highly cited scientific works on this compound?